KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Arbutus Biopharma (ABUS) Accumulated Depreciation & Amortization (2016 - 2025)

Arbutus Biopharma's Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $213000.0 for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 98.36% to $213000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $213000.0, a 98.36% decrease, with the full-year FY2025 number at $213000.0, down 98.36% from a year prior.
  • Accumulated Depreciation & Amortization hit $213000.0 in Q4 2025 for Arbutus Biopharma, down from $352000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for ABUS hit a ceiling of $13.0 million in Q4 2024 and a floor of $213000.0 in Q4 2025.
  • Historically, Accumulated Depreciation & Amortization has averaged $2.8 million across 5 years, with a median of $744000.0 in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 23.0% in 2021 and later crashed 98.36% in 2025.
  • Tracing ABUS's Accumulated Depreciation & Amortization over 5 years: stood at $9.4 million in 2021, then rose by 15.22% to $10.8 million in 2022, then increased by 10.17% to $11.9 million in 2023, then rose by 9.21% to $13.0 million in 2024, then crashed by 98.36% to $213000.0 in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ABUS at $213000.0 in Q4 2025, $352000.0 in Q3 2025, and $341000.0 in Q2 2025.